AU2017209935B2 - New substituted cyanoindoline derivatives as NIK inhibitors - Google Patents

New substituted cyanoindoline derivatives as NIK inhibitors Download PDF

Info

Publication number
AU2017209935B2
AU2017209935B2 AU2017209935A AU2017209935A AU2017209935B2 AU 2017209935 B2 AU2017209935 B2 AU 2017209935B2 AU 2017209935 A AU2017209935 A AU 2017209935A AU 2017209935 A AU2017209935 A AU 2017209935A AU 2017209935 B2 AU2017209935 B2 AU 2017209935B2
Authority
AU
Australia
Prior art keywords
4alkyl
substituted
alkyl
het
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017209935A
Other languages
English (en)
Other versions
AU2017209935A1 (en
Inventor
Simon Richard Green
Gerhard Max GROSS
George Hynd
Edgar Jacoby
Janusz Jozef Kulagowski
Calum Macleod
Samuel Edward MANN
Lieven Meerpoel
Virginie Sophie Poncelet
Olivier Alexis Georges Querolle
Ian Stansfield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2017209935A1 publication Critical patent/AU2017209935A1/en
Application granted granted Critical
Publication of AU2017209935B2 publication Critical patent/AU2017209935B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/535—Organo-phosphoranes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2017209935A 2016-01-22 2017-01-20 New substituted cyanoindoline derivatives as NIK inhibitors Ceased AU2017209935B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16152416.0 2016-01-22
EP16152416 2016-01-22
EP16159651 2016-03-10
EP16159651.5 2016-03-10
PCT/EP2017/051150 WO2017125530A1 (en) 2016-01-22 2017-01-20 New substituted cyanoindoline derivatives as nik inhibitors

Publications (2)

Publication Number Publication Date
AU2017209935A1 AU2017209935A1 (en) 2018-08-09
AU2017209935B2 true AU2017209935B2 (en) 2021-04-01

Family

ID=57868252

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017209935A Ceased AU2017209935B2 (en) 2016-01-22 2017-01-20 New substituted cyanoindoline derivatives as NIK inhibitors

Country Status (20)

Country Link
US (1) US11180487B2 (enExample)
EP (1) EP3405196B1 (enExample)
JP (1) JP6910359B2 (enExample)
KR (1) KR102784966B1 (enExample)
CN (1) CN108697710B (enExample)
AU (1) AU2017209935B2 (enExample)
BR (1) BR112018014675B1 (enExample)
CA (1) CA3011880A1 (enExample)
DK (1) DK3405196T3 (enExample)
ES (1) ES2775449T3 (enExample)
HR (1) HRP20200133T1 (enExample)
HU (1) HUE047684T2 (enExample)
IL (1) IL260500B (enExample)
LT (1) LT3405196T (enExample)
MX (1) MX2018008974A (enExample)
PH (1) PH12018501567A1 (enExample)
SI (1) SI3405196T1 (enExample)
TW (1) TWI739783B (enExample)
WO (1) WO2017125530A1 (enExample)
ZA (1) ZA201804688B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3405464B1 (en) 2016-01-22 2019-12-04 Janssen Pharmaceutica NV New 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors
HRP20200133T1 (hr) 2016-01-22 2020-05-15 Janssen Pharmaceutica Nv Novi supstituirani derivati cijanoindolina kao inhibitori nik
WO2018002219A1 (en) 2016-06-30 2018-01-04 Janssen Pharmaceutica Nv Cyanoindoline derivatives as nik inhibitors
EP3478675B1 (en) 2016-06-30 2020-04-22 Janssen Pharmaceutica NV Heteroaromatic derivatives as nik inhibitors
CN110818690B (zh) 2016-07-26 2021-08-10 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物
US11465984B2 (en) * 2017-09-30 2022-10-11 Shanghai Haihe Pharmaceutical Co., Ltd. Compound having ERK kinase inhibitory activity and use thereof
TW202045008A (zh) 2019-02-01 2020-12-16 印度商皮埃企業有限公司 4-取代的異噁唑/異噁唑啉(雜)芳基脒化合物、及其製備與用途
US20220177459A1 (en) * 2019-04-02 2022-06-09 Hinova Pharmaceuticals Inc. Aromatic amine compound and use thereof in preparation of ar and brd4 dual inhibitors and regulators
CR20210587A (es) 2019-05-31 2022-02-11 Janssen Pharmaceutica Nv Inhibidores de molécula pequeña de quinasa inductora de nf-kb
CA3182276A1 (en) 2020-05-08 2021-12-02 Halia Therapeutics, Inc. Inhibitors of nek7 kinase
EP4393508A4 (en) * 2021-08-23 2024-12-04 Osaka University COMPOSITION FOR SUPPRESSING TRANSDIFFERENTIATION OF MATURE HEPATOCYTES
WO2024059200A1 (en) 2022-09-14 2024-03-21 Halia Therapeutics, Inc. Nek7 inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010042337A1 (en) * 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02003436A (es) 1999-10-07 2002-08-20 Amgen Inc Inhibidores de triazina cinasa.
KR20030024659A (ko) 2000-02-17 2003-03-26 암겐 인코포레이티드 키나제 억제제
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
MXPA03008888A (es) 2001-03-29 2005-03-07 Vertex Pharma Inhibidores de n-terminal c-jun cinasas (jnk) y otras proteinas cinasas.
CA2450934A1 (en) 2001-06-19 2002-12-27 Marco Dodier Pyrimidine inhibitors of phosphodiesterase (pde) 7
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
AU2009263037B2 (en) * 2008-06-26 2011-10-06 Amgen Inc. Alkynyl alcohols as kinase inhibitors
AU2009262068C1 (en) 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
NZ623069A (en) 2009-08-17 2015-11-27 Sloan Kettering Inst Cancer Heat shock protein binding compounds, compositions, and methods for making and using same
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
HUE052110T2 (hu) 2010-07-29 2021-04-28 Rigel Pharmaceuticals Inc AMPK-t aktiváló heterociklusos vegyületek és alkalmazásuk
KR20140048873A (ko) 2011-04-12 2014-04-24 알츠하이머즈 인스티튜트 오브 아메리카, 인크. Ikk-관련 키나제 엡실론 및 tank 결합 키나제 1 억제제의 조성물 및 치료학적 용도
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
MX370588B (es) 2013-08-30 2019-12-16 Ptc Therapeutics Inc Inhibidores de la bmi-1 de pirimidina sustituida.
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為NIK抑制劑的新穎3-(1H-吡唑-4-基)-1H-吡咯并[2,3-c]吡啶衍生物
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作NIK抑制劑之新的1-(4-嘧啶基)-1H-吡唑並[3,2-c]吡啶衍生物
MX358346B (es) 2014-04-04 2018-08-15 Syros Pharmaceuticals Inc Inhibidores de la quinasa dependiente de ciclina 7 (cdk7).
CN106536478A (zh) 2014-05-22 2017-03-22 悉尼大学 ω‑3类似物
WO2016022645A1 (en) 2014-08-06 2016-02-11 Merck Sharp & Dohme Corp. Heterocyclic cgrp receptor antagonists
SG11201701724VA (en) 2014-09-26 2017-04-27 Gilead Sciences Inc Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
CN106928216A (zh) * 2015-12-31 2017-07-07 中国科学院上海药物研究所 具有erk激酶抑制活性的化合物、其制备方法和用途
EP3405464B1 (en) 2016-01-22 2019-12-04 Janssen Pharmaceutica NV New 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors
HRP20200133T1 (hr) 2016-01-22 2020-05-15 Janssen Pharmaceutica Nv Novi supstituirani derivati cijanoindolina kao inhibitori nik
WO2017161028A1 (en) 2016-03-16 2017-09-21 Kura Oncology, Inc. Substituted inhibitors of menin-mll and methods of use
EP3478675B1 (en) 2016-06-30 2020-04-22 Janssen Pharmaceutica NV Heteroaromatic derivatives as nik inhibitors
WO2018002219A1 (en) 2016-06-30 2018-01-04 Janssen Pharmaceutica Nv Cyanoindoline derivatives as nik inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010042337A1 (en) * 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity

Also Published As

Publication number Publication date
ES2775449T3 (es) 2020-07-27
MX2018008974A (es) 2018-11-09
KR102784966B1 (ko) 2025-03-20
PH12018501567A1 (en) 2019-01-28
EP3405196B1 (en) 2019-12-04
KR20180100441A (ko) 2018-09-10
US11180487B2 (en) 2021-11-23
HRP20200133T1 (hr) 2020-05-15
CN108697710B (zh) 2022-02-18
US20210087182A1 (en) 2021-03-25
WO2017125530A1 (en) 2017-07-27
SI3405196T1 (sl) 2020-03-31
LT3405196T (lt) 2020-02-25
CN108697710A (zh) 2018-10-23
ZA201804688B (en) 2022-03-30
DK3405196T3 (en) 2020-03-09
BR112018014675A2 (pt) 2018-12-11
EP3405196A1 (en) 2018-11-28
JP6910359B2 (ja) 2021-07-28
JP2019504067A (ja) 2019-02-14
TW201728577A (zh) 2017-08-16
CA3011880A1 (en) 2017-07-27
TWI739783B (zh) 2021-09-21
BR112018014675B1 (pt) 2023-12-19
AU2017209935A1 (en) 2018-08-09
HUE047684T2 (hu) 2020-05-28
IL260500B (en) 2021-01-31

Similar Documents

Publication Publication Date Title
AU2020256431B2 (en) Bicyclic heterocycles as fgfr4 inhibitors
EP3405196B1 (en) New substituted cyanoindoline derivatives as nik inhibitors
AU2017286380B2 (en) Azabenzimidazole derivatives as PI3K beta inhibitors
AU2017289315B2 (en) Heteroaromatic derivatives as NIK inhibitors
AU2017208555B2 (en) New 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors
AU2014327235B2 (en) New 3-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-c]pyridine derivatives as NIK inhibitors
KR102524622B1 (ko) Nik 억제제로서의 신규 티에노피리미딘 유도체
CA2874546A1 (en) Pyrazolopyrimidone and pyrazolopyridone inhibitors of tankyrase
CN104520290A (zh) 酰氨基螺环酰胺和磺酰胺衍生物
AU2017289317B2 (en) Cyanoindoline derivatives as NIK inhibitors
JP7213193B2 (ja) Nik阻害剤としての新規の置換アザインドリン誘導体
KR20210108433A (ko) 티에노피리디논 화합물
HK1261385B (en) New substituted cyanoindoline derivatives as nik inhibitors
HK1261385A1 (en) New substituted cyanoindoline derivatives as nik inhibitors
EA037358B1 (ru) Новые замещённые производные цианиндолина в качестве nik-ингибиторов

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)